3629 related articles for article (PubMed ID: 29968072)
21. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
22. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
Virág L; Szabó C
Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
[TBL] [Abstract][Full Text] [Related]
23. PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.
Mashimo M; Bu X; Aoyama K; Kato J; Ishiwata-Endo H; Stevens LA; Kasamatsu A; Wolfe LA; Toro C; Adams D; Markello T; Gahl WA; Moss J
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830864
[TBL] [Abstract][Full Text] [Related]
24. Vincristine attenuates N-methyl-N'-nitro-N-nitrosoguanidine-induced poly-(ADP) ribose polymerase activity in cardiomyocytes.
Zhang J; Chatterjee K; Alano CC; Kalinowski MA; Honbo N; Karliner JS
J Cardiovasc Pharmacol; 2010 Mar; 55(3):219-26. PubMed ID: 20375713
[TBL] [Abstract][Full Text] [Related]
25. PARP1 is required for adhesion molecule expression in atherogenesis.
von Lukowicz T; Hassa PO; Lohmann C; Borén J; Braunersreuther V; Mach F; Odermatt B; Gersbach M; Camici GG; Stähli BE; Tanner FC; Hottiger MO; Lüscher TF; Matter CM
Cardiovasc Res; 2008 Apr; 78(1):158-66. PubMed ID: 18093987
[TBL] [Abstract][Full Text] [Related]
26. Inputs and outputs of poly(ADP-ribosyl)ation: Relevance to oxidative stress.
Hegedűs C; Virág L
Redox Biol; 2014; 2():978-82. PubMed ID: 25460733
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
[TBL] [Abstract][Full Text] [Related]
28. DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD
Zhang D; Hu X; Li J; Liu J; Baks-Te Bulte L; Wiersma M; Malik NU; van Marion DMS; Tolouee M; Hoogstra-Berends F; Lanters EAH; van Roon AM; de Vries AAF; Pijnappels DA; de Groot NMS; Henning RH; Brundel BJJM
Nat Commun; 2019 Mar; 10(1):1307. PubMed ID: 30898999
[TBL] [Abstract][Full Text] [Related]
29. The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Kauppinen TM; Swanson RA
Neuroscience; 2007 Apr; 145(4):1267-72. PubMed ID: 17084037
[TBL] [Abstract][Full Text] [Related]
30. Poly(ADP-ribose) polymerase-1 hyperactivation and impairment of mitochondrial respiratory chain complex I function in reperfused mouse hearts.
Zhou HZ; Swanson RA; Simonis U; Ma X; Cecchini G; Gray MO
Am J Physiol Heart Circ Physiol; 2006 Aug; 291(2):H714-23. PubMed ID: 16582021
[TBL] [Abstract][Full Text] [Related]
31. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair.
Dantzer F; Amé JC; Schreiber V; Nakamura J; Ménissier-de Murcia J; de Murcia G
Methods Enzymol; 2006; 409():493-510. PubMed ID: 16793420
[TBL] [Abstract][Full Text] [Related]
32. NAD+ as a metabolic link between DNA damage and cell death.
Ying W; Alano CC; Garnier P; Swanson RA
J Neurosci Res; 2005 Jan 1-15; 79(1-2):216-23. PubMed ID: 15562437
[TBL] [Abstract][Full Text] [Related]
33. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Mukhopadhyay P; Horváth B; Rajesh M; Varga ZV; Gariani K; Ryu D; Cao Z; Holovac E; Park O; Zhou Z; Xu MJ; Wang W; Godlewski G; Paloczi J; Nemeth BT; Persidsky Y; Liaudet L; Haskó G; Bai P; Boulares AH; Auwerx J; Gao B; Pacher P
J Hepatol; 2017 Mar; 66(3):589-600. PubMed ID: 27984176
[TBL] [Abstract][Full Text] [Related]
34. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
35. Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death.
Ying W; Sevigny MB; Chen Y; Swanson RA
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12227-32. PubMed ID: 11593040
[TBL] [Abstract][Full Text] [Related]
36. p38 and JNK have distinct regulatory functions on the development of apoptosis during simulated ischaemia and reperfusion in neonatal cardiomyocytes.
Engelbrecht AM; Niesler C; Page C; Lochner A
Basic Res Cardiol; 2004 Sep; 99(5):338-50. PubMed ID: 15309413
[TBL] [Abstract][Full Text] [Related]
37. Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
Kuchmerovska T; Shymanskyy I; Donchenko G; Kuchmerovskyy M; Pakirbaieva L; Klimenko A
J Diabetes Complications; 2004; 18(4):198-204. PubMed ID: 15207836
[TBL] [Abstract][Full Text] [Related]
38. Beneficial effects of poly (ADP-ribose) polymerase inhibition against the reperfusion injury in heart transplantation.
Fiorillo C; Ponziani V; Giannini L; Cecchi C; Celli A; Nediani C; Perna AM; Liguori P; Nassi N; Formigli L; Tani A; Nassi P
Free Radic Res; 2003 Mar; 37(3):331-9. PubMed ID: 12688429
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
de la Lastra CA; Villegas I; Sánchez-Fidalgo S
Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
[TBL] [Abstract][Full Text] [Related]
40. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
